Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies

Immuno-Oncology Insights 2022; 3(4), 173 –180

DOI: 10.18609/ioi.2022.019

Published: 11 April 2022
Expert Insight
Karin Hägerbrand, Peter Ellmark

Clinical response to cancer immunotherapies such as PD-(L)1 inhibitors is associated with the priming of sufficient levels of tumor infiltrating CD8+ T cells to mount a durable anti-tumor response. However, many cancer patients display poor T cell infiltration or deficiencies in T cell priming. There is therefore a clear unmet clinical need for new therapies that can expand the repertoire of tumor neoantigen specific T cells and increase treatment response rates. CD40 bispecific antibodies (bsAbs) provide a new opportunity to achieve more efficient tumor specific T cell priming. Furthermore, CD40 bsAb based therapies also target macrophages/myeloid cells, which may provide important benefits when combining with other treatment modalities.